The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for the management of hypertension during the past 30 years. The aim of this article is to review the recommendations of the most recent of these -the 1999 WHO-ISH guidelines -as well as previous similar documents, including the earlier 1993 WHO-ISH guidelines and the US Joint National Committee on prevention, detection, evaluation
Introduction
In the 21st century, there is good reason for optimism in the field of cardiology. The recorded decline in cardiovascular mortality in North America, Western Europe, Japan and Australasia since the 1970s 1 is proof that advances in our understanding and management of cardiovascular risk are having a beneficial impact. However, there is little room for complacency since the evidence also shows that coronary heart disease (CHD) continues to be a leading cause of morbidity and mortality in Europe and the USA 2, 3 and is set to become the foremost cause of death and disability in developing countries. 4 Within Westernised societies, there is a marked socioeconomic gradient in cardiovascular disease (CVD) morbidity and mortality. 5 In lower socioeconomic classes, the increased prevalence of risk factors such as smoking, inadequate health education manifest as unhealthy diets and obesity, deficient physical exercise and lack of social support systems combine to increase the risk of CVD significantly. The role of adverse risk factors is emphasised by marked differences in mortality between Eastern and Western Europe that have become obvious during the past three decades. The difference in life expectancy between the European countries with the best and worst mortality statistics is more than 10 years for both genders, and CVD accounts for 54% of this difference. 5 The rapid increase in the incidence of CVD and treatment of high blood pressure, and to outline the supportive evidence that has contributed to their formulation. Moreover, the 1999 guidelines have added a new class of antihypertensive drugs, the angiotensin II receptor antagonists, to the armamentarium of therapeutic agents recommended for the early treatment of hypertension. Particular attention will be paid in this paper to the role of these agents in hypertension, focusing on candesartan cilexetil as a representative of its class.
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in the former socialist republics and in developing countries is of particular concern. 6 For many physicians and policy makers with limited financial and physical resources, the bases for the effective management of CVD and for prioritising patients for primary prevention strategies remain incomplete. 7 However, the identification of highrisk individuals who already have CVD, as well as apparently healthy individuals with high levels of cardiovascular risk, remains an important part of everyday clinical practice. [8] [9] [10] These requirements emphasise the need for continuing collaboration between specialist groups to define a unified approach to cardiovascular risk management.
The problems presented by the need to define cardiovascular risk factors are illustrated by the fact that, despite improved awareness of hypertension and its implications, including treatment and control, many hypertensive individuals in the USA are unaware of their condition and many more are untreated or treated inadequately. 11 Similar findings have been reported for several European countries.
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The cardiovascular risk associated with hypertension
Major prospective observational studies have demonstrated a strong correlation between the magnitude of systolic blood pressure (SBP), diastolic blood pressure (DBP) and the risk of developing strokes and CHD. 3, 15, 16 The relationship between DBP (as well as SBP) and CVD is strong, continuous and graded 16 ( Figure 1 ). Hypertension has also been identified as a cardinal risk factor for the develop- Figure 1 Relationship between DBP and relative risks of CHD and stroke. n = 420, 000. Mean follow-up 10 years. Adapted with permission from MacMahon et al. 15 Blood pressure, stroke and coronary heart disease, Part 1. Lancet 335: 765-774. © by The Lancet Ltd., 1990. ment of congestive heart failure 17, 18 and end-stage renal disease. 19 It is not only the severely hypertensive patient who is at risk of cardiovascular complications. In a review of prospective observational studies, threequarters of all strokes were found to have occurred in the 95% of individuals who had a usual SBP of Ͻ155 mm Hg and DBP of Ͻ95 mm Hg, 20 while borderline blood pressures of 140-159 mm Hg were associated with a three-fold increase in the incidence of strokes in individuals in the Framingham study. 3 Indeed, comparison of the percentage of excess (attributable) deaths between individuals with SBP in the range of 140-159 mm Hg (39.6%) or Ͼ160 mm Hg (22.9%) shows that the majority of deaths do not occur in patients with blood pressures in the conventional hypertensive range (Ͼ160 mm Hg). Thus, patients with clinically apparent mild hypertension constitute the majority of hypertensive patients at risk of cardiovascular complications. 16 In this connection, there is often uncertainty among clinicians about how to manage the latter patients. For these reasons, the World Health Organisation-International Society of Hypertension (WHO-ISH) guidelines concentrate on the management of patients with mild hypertension. 
Hypertension in the elderly
One of the problems associated with the treatment of hypertension is illustrated by evidence that clinicians appear more reluctant to treat older patients than younger patients. 21 In general, blood pressure increases with age and the prevalence of hypertension in individuals older than 75 years is 65% in men and 74% in women. 22 Hypertension doubles the risk of cardiovascular events in both elderly men and women and the risk of adverse cardiovascular events resulting from high blood pressure exceeds that imposed by elevated cholesterol, smoking or diabetes. 23 Similarly, in the Framingham study, elderly individuals with isolated systolic hypertension suffered two to five times the cardiovascular mortality of the general population and had a greatly increased risk of stroke. 24 Since the elderly have a greater risk of CVD, antihypertensive treatment is likely to produce a greater absolute benefit in the elderly than in younger patients at all levels of blood pressure. 25 For example, a number of randomised controlled trials have shown that treatment with antihypertensive drugs is clearly beneficial and that this benefit extends to the very elderly, up to 80 years of age. 26 Benefits of treatment have been demonstrated among older patients with classical hypertension (raised SBP and DBP), as well as among older patients with systolic hypertension (raised SBP alone). 6 
Guidelines for the treatment of hypertension
The prevention and treatment of hypertension both from the point of view of individual patient care and in terms of population health thus presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for the management of hypertension during the past 30 years. The aim of the present article is to review the recommendations of the most recent of these -the 1999 WHO-ISH guidelines 6 -as well as previous similar documents, including the earlier 1993 WHO-ISH guidelines 27 and the US Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure 28 and to outline the supportive evidence that has contributed to their formulation. Moreover, the 1999 guidelines have added a new class of antihypertensive drugs, the angiotensin II receptor antagonists (AIIRAs), to the armamentarium of therapeutic agents recommended for the early treatment of hypertension, so that particular attention will be paid to the role of these agents, focusing on candesartan cilexetil as a representative of its class.
Benefits of treating hypertension
There is overwhelming evidence to confirm the beneficial effects of lowering blood pressure in reducing the risk of coronary artery and cerebrovascular events. 26 For example, Framingham data, comparing hypertensive patients treated for two decades with untreated hypertensive patients, showed an absolute reduction of cardiovascular mortality by 60% in treated patients and a reduction of all-cause mortality by 30%. 26 Moreover, it has been shown in prospective observational studies that a long-term difference of 5-6 mm Hg in usual DBP is associated with a decrease of approximately 35-40% in incidence of strokes and approximately 20-25% in incidence of CHD. 29 Large, well-conducted trials have confirmed that blood pressure reduction with ␤-blockers and thiazide diuretics lessens the risk of stroke, CHD and mortality. 29, 30 The incidence of stroke was reduced by 42% and of CHD by 14%; however, while nearly all the epidemiologically expected stroke reduction was recorded early in the studies, only half the expected reduction in CHD occurred during the observation period of the trials. 29 In this context, it is interesting to note that data from the Framingham study have shown that the long-term benefits of the control of hypertension are much greater than those observed in earlier short-term trials. 31, 32 Lowering of blood pressure also protects against congestive heart failure 18,33 and end-stage renal disease 19 and prevents progression to more severe hypertension. 33 Reduction in blood pressure and treatment of isolated systolic hypertension produce considerable benefit in the elderly, reducing the risk of stroke by 36-42% and fatal or non-fatal cardiac endpoints by 26%. 34, 35 Similarly, the results of five randomised controlled trials employing pharmacological reduction of blood pressure in elderly hypertensive patients (mean age of 72 years) showed that the incidence of stroke was reduced by 34% and of CHD by 19%, proportions that are similar to those observed in trials involving predominantly younger patients. 36 Unfortunately, treated hypertensive patients still die prematurely from CVD, 37 so that it remains important to define and implement the best currently available management of hypertension. Carefully considered guidelines provide a means of achieving this goal.
Patient stratification
The majority of guidelines are in agreement that, for patients with high-normal blood pressure values (SBP 130-139 mm Hg; DBP 85-89 mm Hg) or only mild (Grade 1) hypertension (Table 1) , lifestyle modification is usually sufficient -providing the patient can be persuaded to make and sustain the necessary changes. 6 For moderate or severe hypertension (Grade 2 or 3), or for patients with additional risk factors (Table 1) , more aggressive pharmacological intervention as well as lifestyle changes are recommended. 6, 28 The minimal acceptable level of con-
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trol of blood pressure as recommended in the BHS guidelines is Ͻ150 mm Hg SBP and Ͻ90 mm Hg DBP, while optimal blood pressure targets are lower: SBP Ͻ140 mm Hg and DBP Ͻ85 mm Hg. 38 In patients with renal disease or diabetes, however, SBP/DBP should be reduced to Ͻ130/85 mm Hg 39, 40 and, according to the 1999 WHO-ISH guidelines, similar values should also be pursued in young and middle-aged hypertensive patients. 6 It is necessary to emphasise that decisions about the management of patients with hypertension should not be based on the level of blood pressure alone but also on the presence of other risk factors, concomitant diseases such as diabetes, target-organ damage and CVD or renal disease, as well as other aspects of the patient's personal, medical and social situation. 6 Recently, the HOPE study 41 
Goals of treatment
The primary goal of treatment of the patient with high blood pressure is to achieve the maximal reduction in the total risk of cardiovascular morbidity and mortality in addition to lowering of blood pressure. This objective requires treatment of all the identified reversible risk factors including: smoking, raised levels of circulating cholesterol, diabetes and the appropriate management of associated clinical conditions, as well as the treatment of hypertension.
Is there an optimal target blood pressure?
Although a progressive risk reduction in cerebrovascular and renal disease with decreasing DBP has been recorded, the possibility that excessive lowering of DBP may increase risks in patients with preexisting CHD has been discussed. 28, 42 However, recent results from the Hypertension Optimal Treatment (HOT) randomised trial 39 showed no evidence of a J-shaped curvilinear relationship between blood pressure reduction and the risk of major cardiovascular events (strokes, myocardial infarction and mortality); most of the benefit, in terms of reduced cardiovascular risk, was achieved by lowering blood pressure to about 140/85 mm Hg, and there was little further benefit, but no significant additional risk, when blood pressures fell further. Other studies have also shown that the relationship between blood pressure lowering and risk reduction does not appear to have a lower threshold. 43 In addition, a substudy of the HOT trial showed that quality of life was linked to the level of blood pressure attained with treatment -the lower the blood pressure, the better the quality of life. 28 and by the WHO-ISH. 6 The former recommended the initial use of ␤-blockers and thiazide diuretics for all cases of uncomplicated hypertension, with other classes of blood pressure-lowering drugs to be used only in cases of inadequate response or comorbidity. On the other hand, the WHO-ISH has adopted a more liberal policy, with equal emphasis given to the value of different treatments, depending on the patient group.
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It is worth emphasising that there is no reliable evidence from randomised controlled trials to indicate that there are significant differences between different treatment regimens in their effects on blood pressure, although there are important differences in the side-effect profiles of the different classes of drugs. The choice of antihypertensive drugs should therefore be based on a number of criteria, including socioeconomic factors that determine drug availability in different countries, the cardiovascular risk profile of the individual patient, variations in patient responses to drugs of different classes, the possibility of interactions with drugs used for concomitant conditions and the strength of the evidence for reduction of cardiovascular risk with the drug class in question.
In this connection, there is no evidence that the benefits resulting from treatment are specifically due to diuretics and ␤-blockers, rather than the lowering of blood pressure per se. 45 Several other studies published since 1993 have confirmed this finding, using a variety of drugs: Shanghai Trial Of Nifedipine in the Elderly (STONE); 46 SYSTolic hypertension in EURope trial (Syst-Eur); 35 SYSTolic hypertension in China trial (Syst-China); 47 HOT; 39 CAPtopril Prevention Project (CAPPP); 48 United Kingdom Prospective Diabetes Study (UKPDS); 40 and the Swedish Trial in Old Patients with hypertension-2 (STOP II). 49 In each of these trials, a definite correlation between the lowering of blood pressure and clinical benefit was demonstrated, confirming that it was the lowering of blood pressure rather than the drug regimen that produced the beneficial effects. 45 Moreover, two long-term double-blind studies have compared the major classes of antihypertensive drugs (thiazide diuretics, ␤-blockers, calcium antagonists, ACE inhibitors and ␣-blockers) and, overall, have shown no important differences with regard to the efficacy of antihypertensive therapy or resulting quality of life. 50, 51 However, a third study has shown differences in response between classes of drugs, related to the fact that in men, age and race have an important effect on the response to single-drug therapy. These factors should perhaps be considered in the initial choice of drug. 52 The most recently introduced class of antihypertensive drugs, the AIIRAs, were not represented in these studies. However, a meta-analysis of six European placebo-controlled, randomised, parallelgroup, dose-response studies using candesartan cilexetil has shown a clinically significant dosedependent antihypertensive effect, irrespective of age and gender 53 ( Figure 2 ). These and similar studies with other AIIRAs such as losartan and valsartan 53 have provided evidence that this class of antihypertensive agent is appropriate for the treatment of hypertension. Consequently, the latest WHO-ISH guidelines 6 recommend this class of drug together with the others included in the 1993 guidelines. 27 These guidelines give more scope to physicians to exercise their personal judgement regarding the needs of individual patients and permit the selection of an antihypertensive regimen based not only on efficacy, but also on other pertinent factors, such as the side-effect profile of the drug.
24-h blood pressure control
An important feature of an antihypertensive treatment regimen is its ability to maintain control of blood pressure during both day and night. Greater protection against cardiovascular complications may accompany a more effective 24-h control of blood pressure 45, 54 so that the WHO-ISH guidelines 6 recommend the use of antihypertensive treatment that can provide a constant 24-h control of blood pressure. Candesartan cilexetil does not alter the natural diurnal variations in DBP and, indeed, one study has shown that the profile of the ambulatory blood pressure with candesartan was consistently lower than, but parallel to, that obtained from patients receiving placebo. 
Combined therapy
Combinations of agents from the different classes of antihypertensive drugs have been shown to produce greater blood pressure reductions than those achieved with single-agent therapy. The HOT study, 39 in which blood pressure was lowered to below 90 mm Hg in more than 90% of patients, demonstrated that combination therapy was necessary for 70% of participants. Thus, combinations of drugs with fully additive hypotensive actions can achieve blood pressure reductions that are approximately twice as great as those obtained with a single drug, with hypotensive effects that are typically 12-22 mm Hg for SBP and 7-14 mm Hg for DBP in patients with pre-treatment blood pressures of 160/95 mm Hg. 6 For this reason, it has been noted that for most drugs used to treat hypertension, combinations of drugs will be required to achieve recommended targets of blood pressure control. 38 A good first-choice hypotensive agent must therefore be effective when used in combination with other drugs, to permit use in patients for whom combination therapy is indicated. In this connection, the AIIRAs have been shown to be effective in combination with diuretics, so that the combination of AIIRAs and diuretics is recommended in the WHO-ISH guidelines. 6 For example, candesartan cilexetil has been used in combination with hydrochlorothiazide, so that with increasing doses of candesartan, the combination treatment resulted in additional reductions in blood pressure.
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Compliance
By its very nature, antihypertensive treatment must be long term, since it is the chronic long-term nature of hypertension that gives rise to many of its cardiovascular sequelae. Moreover, it has been suggested that a better therapeutic effect is seen during later stages of treatment. 31, 32 Patient age and dosing frequency are clinically important independent covariates that together with the class of antihypertensive drug, predict long-term compliance. 57 At 12 months follow-up, the percentage of patients continuing with AIIRA therapy was higher (64%) than the percentages continuing to take ACE inhibitors (58%), calcium antagonists (50%), ␤-blockers (43%) or thiaJournal of Human Hypertension zide diuretics (38%). 57 The reasons for these variations in compliance are complex but may be related, in part, to drug side-effect profiles.
An important determinant of the long-term efficacy of treatment is the ability of antihypertensive drugs to maintain blood pressure control for extended periods of time. Candesartan cilexetil had been shown to maintain antihypertensive effects and tolerability during 12 months of treatment 58 ( Figure 3) .
However, the long-term effectiveness of any drug will be compromised if patient compliance with treatment is poor. Overall, compliance decreases with time to approximately 50% after 1 year. 59 In a study examining compliance during the first year of treatment, 60 the initial choice of drug was shown to influence persistence with treatment. After 6 months, persistence with therapy was 80% for diuretics, 85% for ␤-blockers, 86% for calcium channel blockers and 89% for ACE inhibitors. Persistence was inversely related to therapeutic turbulence. These findings appear to challenge the recommendations that diuretics and ␤-blockers should be prescribed first for the treatment of hypertension.
Diuretics are well tolerated in low doses, but high doses can cause potassium depletion, reduced glucose tolerance, ventricular ectopic beats and impotence. 6 ␤-blockers should be avoided in patients with obstructive airway disease and peripheral vascular disease. 6 ACE inhibitors are generally well tolerated but frequently cause a dry cough that is troublesome to patients and can also cause a rare, but life-threatening angioedema. 61 Calcium antagonists can produce tachycardia, flushing, dependent oedema and (with verapamil) constipation. Alphablockers can cause postural hypotension that can be troublesome in the elderly. AIIRAs have a particularly good side-effect profile and do not cause the dry cough associated with ACE inhibitors. 62 In double-blind clinical trials, patients with mild-to-moderate hypertension treated with candesartan cilexetil experienced an incidence of adverse events that was comparable with that seen in placebo-treated patients. 53 Candesartan cilexetil was equally well tolerated by women and men and by younger or elderly (у65 years) patients as well as the very elderly (у75 years) 63 (the latter being a population group Figure 3 Time course of sitting DBP in patients receiving long-term (12 months') treatment with candesartan cilexetil. Adapted from Sever and Holzgreve. 58 that is often beset by a variety of tolerability problems).
Expanding horizons: the added benefits of antihypertensive treatment
Recent evidence suggests that antihypertensive therapy is important not only for the treatment of CVD, but may also reduce the incidence of dementia and improve the prognosis of elderly diabetics with hypertension. Thus, the HOPE study 64 showed that treatment of hypertension was not hazardous to cognitive function in older patients and implied that long-term adequate control of blood pressure might reverse the cognitive impairment associated with pre-existing hypertension. Moreover, a report from the Syst-Eur trial 65 has shown that in elderly individuals with isolated systolic hypertension, antihypertensive treatment is associated with a 50% lower incidence of dementia (3.8 cases per 1000 patient years in the active treatment group compared with 7.7 cases per 1000 patient years in the placebo group; P = 0.05). SBP and DBP were 8.3 mm Hg and 3.8 mm Hg lower (P Ͻ 0.001), respectively, in the active treatment group. However, this study had some limitations, among which were the low number of dementia cases, and the large discrepancies between laboratory estimates of mental and cognitive function and the actual clinical diagnoses of dementia. Despite these defects, the underlying message of this study has exciting and far-reaching implications. Improvements in cognitive function potentially could affect the quality of life of large numbers of people, benefiting not only elderly patients themselves, but also carers and families.
These interesting findings are being extended in the Study on COgnition and Prognosis in the Elderly (SCOPE). This trial has been designed to investigate the effects of candesartan cilexetil on morbidity and mortality as primary endpoints with secondary endpoints of changes in cognitive function, quality of life and effects on health economics.
A number of trials have recently shown the benefits of antihypertensive treatment in protecting against the microvascular and macrovascular disease that complicate type 2 diabetes. In the UKPDS trial, 40 antihypertensive therapy was found to be more effective than tight glycaemic control in protecting against microvascular and macrovascular complications and was the only intervention that improved survival in these patients. Similarly, in the diabetic cohort of the HOT study, 39 there were 50% fewer cardiovascular adverse events when DBP was maintained below 80 mm Hg. Based on current evidence and the overall cardiovascular event rate of Ͼ3% per year in this group, a blood pressure of у140/90 mm Hg would seem to justify treatment with an antihypertensive agent.
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Conclusion
There can no longer be doubts about the wisdom of treating hypertension. The public health benefits of primary prevention of hypertension as well as the benefits to individual patients of interventions to lower blood pressure are well documented. Guidelines have been formulated to facilitate these goals of treatment. The latest class of antihypertensive drugs, the AIIRAs, have recently been added to these guidelines and should prove useful in the management of the hypertensive patient. Guidelines can provide clinicians with reliable evidence-based recommendations that leave scope for individual physicians to exercise their clinical judgement, and their use should be encouraged because, at present, implementation of these guidelines is less than optimal. For example, canvassing of the audience at a symposium at the European Society of Hypertension meeting held in Milan in June 1999 revealed that only 37% of clinicians used risk tables to aid in patient management.
